A Phase 2 interventional study of Inarigivir Soproxil and TAF in Chronic Hepatitis B, sponsored by Gilead Sciences. Terminated at 13 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-04-04.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic — 5 open to participants now, 10 under way, 1 of them phase 3. tenofovir alafenamide · Hepatitis B, Chronic.
Among the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, this one is the 14th largest by enrollment, is one of 2 that started in 2018, is one of 4 in phase 2, and was the 7th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →5 of the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic are open now, in 4 countries. Recruiting first, the newest first:
Institute of Liver and Biliary Sciences, India · Sites in India
Ages 18–70
First People's Hospital of Hangzhou · Sites in China
Ages 20–40 · Women only
Jidong Jia · Sites in China
Ages 18–69
National Cheng-Kung University Hospital · Sites in Taiwan
Ages 20+
The Task Force for Global Health · Sites in Thailand
Healthy volunteers
By country, each count listing its studies:
tenofovir alafenamide: first FDA approval 2015 (GENVOYA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 1 · Phase 4 14
First in 2012; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 123 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 124 across the 26 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 26 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
34 studies in Hepatitis B, Chronic by Gilead Sciences: none open now, 2 under way, 1 of them phase 3. Of 31 finished, 24 (77%) have results posted.
Among the 34 studies in Hepatitis B, Chronic by Gilead Sciences, this one is the 14th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2018, is one of 15 in phase 2, and was the 30th registered.
Gilead Sciences’s Hepatitis B, Chronic studies by the year they started, since 2002.
1 of the studies testing tenofovir alafenamide in Hepatitis B, Chronic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07203118Phase 3Xi'an Xintong Pharmaceutical Research Co.,Ltd.A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, from their registry updates:
Among Gilead Sciences’s 34 in Hepatitis B, Chronic:
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to evaluate the safety and tolerability of the 12 week treatment regimens of inarigivir soproxil plus tenofovir alafenamide (TAF) or commercially available nucleoside/nucleotide (NUC) in adults with chronic hepatitis B (CHB), to evaluate the antiviral activity of 12 weeks of inarigivir soproxil plus TAF versus TAF alone in viremic CHB participants (Groups 1-3, 5), and to evaluate the antiviral activity of 12 weeks of inarigivir soproxil with commercially available NUC(s) in virally suppressed CHB participants (Group 4).
Key Inclusion Criteria:
Groups 1-3 and 5:
Group 4:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Viremic participants will be administered inarigivir soproxil 50 mg (2 x 25 mg capsules) once daily orally 1 hour before or 1 hour after a meal plus TAF 25 mg tablet once daily orally with food for 12 weeks followed by TAF 25 mg tablet once daily orally with food for 36 weeks.
Drug: Inarigivir Soproxil · Drug: TAF
Viremic participants will be administered TAF 25 mg tablet once daily orally with food for 48 weeks.
Drug: TAF
Viremic participants will be administered inarigivir soproxil 200 mg (2 x 100 mg tablets) once daily orally 1 hour before or 1 hour after a meal plus TAF 25 mg tablet once daily orally with food for 12 weeks followed by TAF 25 mg tablet once daily orally with food for 36 weeks
Drug: Inarigivir Soproxil · Drug: TAF
Virally suppressed participants receiving commercially available nucleoside/nucleotide (NUC) will be administered inarigivir soproxil 100 mg tablet once daily orally 1 hour before or 1 hour after a meal for 12 weeks. Participants will continue commercially available NUCs for 48 weeks.
Drug: Inarigivir Soproxil
Viremic participants will be administered inarigivir soproxil 400 mg (2 x 200 mg tablets) once daily orally 1 hour before or 1 hour after a meal plus TAF 25 mg tablet once daily orally with food for 12 weeks followed TAF 25 mg tablet once daily orally with food for 36 weeks.
Drug: Inarigivir Soproxil · Drug: TAF
Administered orally once daily one hour before or one hour after a meal
Also known as: SB 9200, GS-9992
Administered orally once daily with food
Also known as: GS-7340, Vemlidy®
Percentage of Participants With ≥ 0.5 log10 IU/mL Decline in HBsAg From Baseline at Week 12 (Groups 1-3 and 5)
Time frame: Baseline, Week 12
Percentage of Participants With ≥ 0.5 log10 IU/mL Decline in HBsAg From Baseline at Week 12 (Group 4)
Time frame: Baseline, Week 12
Percentage of Participants With ≥ 1 log10 IU/mL Decline in HBsAg From Baseline at Week 12 (Groups 1 Through 3 and 5)
Time frame: Baseline, Week 12
Percentage of Participants With ≥ 1 log10 IU/mL Decline in HBsAg From Baseline at Week 12 (Group 4)
Time frame: Baseline, Week 12
Percentage of HBeAg-positive Participants Who Achieved HBeAg Loss and Seroconversion at Weeks 12, 24, 36, and 48 (Groups 1 Through 3 and 5)
HBeAg loss was defined as qualitative HBeAg result changing from positive at baseline to negative at post-baseline visit. HBeAg seroconversion was defined as HBeAb changing from negative or missing at baseline to positive at any postbaseline visit. Participants who had missing information were assumed to have no HBeAg loss and no HBeAg seroconversion.
Time frame: Baseline, Weeks 12, 24, 36, and 48
Percentage of HBeAg-positive Participants Who Achieved HBeAg Loss and Seroconversion at Weeks 12, 24, 36, and 48 (Group 4)
HBeAg loss was defined as qualitative HBeAg result changing from positive at baseline to negative at post-baseline visit. HBeAg seroconversion was defined as HBeAb changing from negative or missing at baseline to positive at any postbaseline visit. Participants who had missing information were assumed to have no HBeAg loss and no HBeAg seroconversion.
Time frame: Baseline, Weeks 12, 24, 36, and 48
Percentage of Participants Who Achieved HBsAg Loss at Weeks 12, 24, 36, and 48 (Groups 1 Through 3 and 5)
HBeAg loss was defined as qualitative HBeAg result changing from positive at baseline to negative at post-baseline visit. Participants who had missing information were assumed to have no HBeAg loss.
Time frame: Baseline, Weeks 12, 24, 36, and 48
Percentage of Participants Who Achieved HBsAg Loss at Weeks 12, 24, 36, and 48 (Group 4)
HBeAg loss was defined as qualitative HBeAg result changing from positive at baseline to negative at post-baseline visit.
Time frame: Baseline, Weeks 12, 24, 36, and 48
Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Had HBV DNA ≥ 69 IU/mL (Groups 1 Through 3 and 5)
Time frame: Baseline, Week 48
Percentage of Participants Experiencing Hepatitis B Virus (HBV) Virologic Breakthrough During 12 Weeks of Inarigivir Soproxil Treatment (Group 4)
Virologic breakthrough was defined as HBV deoxyribonucleic acid (DNA) ≥69 IU/mL for 2 consecutive visits
Time frame: Baseline up to Week 12
Change From Baseline in HBV DNA at Weeks 12, 16, 24, 36, and 48 (Groups 1 Through 3 and 5)
Time frame: Baseline, Weeks 12, 16, 24, 36, and 48
Change From Baseline in HBsAg at Weeks 12, 16, 24, 36, and 48 (Groups 1 Through 3 and 5)
Time frame: Baseline, Weeks 12, 16, 24, 36, and 48
Change From Baseline in HBsAg at Weeks 12, 16, 24, 36, and 48 (Group 4)
Time frame: Baseline, Weeks 12, 16, 24, 36, and 48
Participants were enrolled at study sites in Hong Kong and South Korea. The first participant was screened on 28 February 2018. The last study visit occurred on 26 January 2021.
| Milestone | Group 1: Inarigivir Soproxil 50 mg + TAF | Group 2: TAF | Group 3: Inarigivir Soproxil 200 mg + TAF | Group 4: Inarigivir Soproxil 100 mg + Commercially Available NUC(s) | Group 5: Inarigivir Soproxil 400 mg + TAF |
|---|---|---|---|---|---|
| Started | 30 | 12 | 30 | 21 | 30 |
| Completed | 16 | 9 | 16 | 18 | 12 |
| Not completed | 14 | 3 | 14 | 3 | 18 |
| Withdrew: Started commercial hepatitis b virus therapy | 10 | 3 | 11 | 3 | 17 |
| Withdrew: Withdrew consent | 1 | 0 | 3 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 | 0 |
| percentage of participants | Group 1: Inarigivir Soproxil 50 mg + TAF | Group 2: TAF | Group 3: Inarigivir Soproxil 200 mg + TAF | Group 5: Inarigivir Soproxil 400 mg + TAF |
|---|---|---|---|---|
| Percentage of Participants With ≥ 0.5 log10 IU/mL Decline in HBsAg From Baseline at Week 12 (Groups 1-3 and 5) | 23.3 (9.9 to 42.3) | 25.0 (5.5 to 57.2) | 0 (0.0 to 11.6) | 6.7 (0.8 to 22.1) |
| percentage of participants | Group 4: Inarigivir Soproxil 100 mg + Commercially Available NUC(s) |
|---|---|
| Percentage of Participants With ≥ 0.5 log10 IU/mL Decline in HBsAg From Baseline at Week 12 (Group 4) | 0 (0.0 to 16.1) |
| percentage of participants | Group 1: Inarigivir Soproxil 50 mg + TAF | Group 2: TAF | Group 3: Inarigivir Soproxil 200 mg + TAF | Group 5: Inarigivir Soproxil 400 mg + TAF |
|---|---|---|---|---|
| Percentage of Participants With ≥ 1 log10 IU/mL Decline in HBsAg From Baseline at Week 12 (Groups 1 Through 3 and 5) | 0 (0.0 to 11.6) | 16.7 (2.1 to 48.4) | 0 (0.0 to 11.6) | 0 (0.0 to 11.6) |
| percentage of participants | Group 4: Inarigivir Soproxil 100 mg + Commercially Available NUC(s) |
|---|---|
| Percentage of Participants With ≥ 1 log10 IU/mL Decline in HBsAg From Baseline at Week 12 (Group 4) | 0 (0.0 to 16.1) |
HBeAg loss was defined as qualitative HBeAg result changing from positive at baseline to negative at post-baseline visit. HBeAg seroconversion was defined as HBeAb changing from negative or missing at baseline to positive at any postbaseline visit. Participants who had missing information were assumed to have no HBeAg loss and no HBeAg seroconversion.
| percentage of participants | Group 1: Inarigivir Soproxil 50 mg + TAF | Group 2: TAF | Group 3: Inarigivir Soproxil 200 mg + TAF | Group 5: Inarigivir Soproxil 400 mg + TAF |
|---|---|---|---|---|
| Week 12 | 5.6 | 0 | 0 | 0 |
| Week 24 | 5.6 | 0 | 0 | 0 |
| Week 36 | 5.6 | 0 | 0 | 0 |
| Week 48 | 0 | 0 | 0 | 0 |
HBeAg loss was defined as qualitative HBeAg result changing from positive at baseline to negative at post-baseline visit. HBeAg seroconversion was defined as HBeAb changing from negative or missing at baseline to positive at any postbaseline visit. Participants who had missing information were assumed to have no HBeAg loss and no HBeAg seroconversion.
| percentage of participants | Group 4: Inarigivir Soproxil 100 mg + Commercially Available NUC(s) |
|---|---|
| Week 12 | 14.3 |
| Week 24 | 14.3 |
| Week 36 | 14.3 |
| Week 48 | 14.3 |
HBeAg loss was defined as qualitative HBeAg result changing from positive at baseline to negative at post-baseline visit. Participants who had missing information were assumed to have no HBeAg loss.
| percentage of participants | Group 1: Inarigivir Soproxil 50 mg + TAF | Group 2: TAF | Group 3: Inarigivir Soproxil 200 mg + TAF | Group 5: Inarigivir Soproxil 400 mg + TAF |
|---|---|---|---|---|
| Week 12 | 0 | 0 | 0 | 0 |
| Week 24 | 0 | 0 | 0 | 0 |
| Week 36 | 0 | 0 | 0 | 0 |
| Week 48 | 0 | 0 | 0 | 0 |
HBeAg loss was defined as qualitative HBeAg result changing from positive at baseline to negative at post-baseline visit.
| percentage of participants | Group 4: Inarigivir Soproxil 100 mg + Commercially Available NUC(s) |
|---|---|
| Week 12 | 0 |
| Week 24 | 0 |
| Week 36 | 0 |
| Week 48 | 0 |
| Participants | Group 1: Inarigivir Soproxil 50 mg + TAF | Group 2: TAF | Group 3: Inarigivir Soproxil 200 mg + TAF | Group 5: Inarigivir Soproxil 400 mg + TAF |
|---|---|---|---|---|
| Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Had HBV DNA ≥ 69 IU/mL (Groups 1 Through 3 and 5) | 4 | 0 | 0 | 4 |
Virologic breakthrough was defined as HBV deoxyribonucleic acid (DNA) ≥69 IU/mL for 2 consecutive visits
| percentage of participants | Group 4: Inarigivir Soproxil 100 mg + Commercially Available NUC(s) |
|---|---|
| Percentage of Participants Experiencing Hepatitis B Virus (HBV) Virologic Breakthrough During 12 Weeks of Inarigivir Soproxil Treatment (Group 4) | 0 |
| log10 IU/mL | Group 1: Inarigivir Soproxil 50 mg + TAF | Group 2: TAF | Group 3: Inarigivir Soproxil 200 mg + TAF | Group 5: Inarigivir Soproxil 400 mg + TAF |
|---|---|---|---|---|
| Baseline | 7.06 ± 1.530 | 7.06 ± 1.757 | 6.30 ± 1.365 | 6.61 ± 1.479 |
| Change at Week 12 | -4.18 ± 0.959 | -4.24 ± 1.340 | -4.02 ± 0.854 | -3.93 ± 0.817 |
| Change at Week 16 | -4.58 ± 1.023 | -4.65 ± 1.326 | -4.29 ± 0.946 | -4.23 ± 0.869 |
| Change at Week 24 | -5.02 ± 1.101 | -5.25 ± 1.510 | -4.67 ± 1.049 | -4.76 ± 1.013 |
| Change at Week 36 | -5.27 ± 1.194 | -5.53 ± 1.610 | -4.78 ± 1.207 | -4.92 ± 1.129 |
| Change at Week 48 | -5.36 ± 1.225 | -5.25 ± 1.839 | -4.83 ± 1.162 | -4.93 ± 1.370 |
| log10 IU/mL | Group 1: Inarigivir Soproxil 50 mg + TAF | Group 2: TAF | Group 3: Inarigivir Soproxil 200 mg + TAF | Group 5: Inarigivir Soproxil 400 mg + TAF |
|---|---|---|---|---|
| Baseline | 3.933 ± 0.8058 | 4.118 ± 0.6543 | 3.529 ± 0.8835 | 3.418 ± 0.8075 |
| Change at Week 12 | -0.244 ± 0.3443 | -0.435 ± 0.5320 | 0.016 ± 0.2850 | -0.026 ± 0.3805 |
| Change at Week 16 | -0.282 ± 0.3954 | -0.479 ± 0.5429 | 0.014 ± 0.2916 | -0.082 ± 0.4262 |
| Change at Week 24 | -0.310 ± 0.4303 | -0.482 ± 0.5119 | -0.021 ± 0.3171 | -0.104 ± 0.5000 |
| Change at Week 36 | -0.330 ± 0.4363 | -0.524 ± 0.5430 | -0.055 ± 0.4213 | -0.209 ± 0.5319 |
| Change at Week 48 | -0.322 ± 0.4311 | -0.517 ± 0.5617 | -0.045 ± 0.4778 | -0.235 ± 0.5429 |
| log10 IU/mL | Group 4: Inarigivir Soproxil 100 mg + Commercially Available NUC(s) |
|---|---|
| Baseline | 3.211 ± 0.5536 |
| Change at Week 12 | -0.017 ± 0.0417 |
| Change at Week 16 | -0.010 ± 0.0645 |
| Change at Week 24 | -0.039 ± 0.0925 |
| Change at Week 36 | -0.037 ± 0.0939 |
| Change at Week 48 | -0.073 ± 0.1120 |
Collected over All-cause mortality: From randomization/enrollment up to Week 48 + 3 days Adverse events: Groups 1, 2, 3, 5: From first dose up to Week 48 + 3 days Group 4: From first dose up to Week 12 + 30 days (for Group 4, adverse events were planned to be collected only up to Week 12 + 30 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Inarigivir Soproxil 50 mg + TAF | 0/30 (0%) | 1/30 (3.3%) | 8/30 (26.7%) |
| Group 2: TAF | 0/12 (0%) | 1/12 (8.3%) | 7/12 (58.3%) |
| Group 3: Inarigivir Soproxil 200 mg + TAF | 0/30 (0%) | 1/30 (3.3%) | 15/30 (50%) |
| Group 4: Inarigivir Soproxil 100 mg + Commercially Available NUC(s) | 0/21 (0%) | 0/21 (0%) | 9/21 (42.9%) |
| Group 5: Inarigivir Soproxil 400 mg + TAF | 0/30 (0%) | 1/30 (3.3%) | 9/30 (30%) |
| Event | Group 1: Inarigivir Soproxil 50 mg + TAF | Group 2: TAF | Group 3: Inarigivir Soproxil 200 mg + TAF | Group 4: Inarigivir Soproxil 100 mg + Commercially Available NUC(s) | Group 5: Inarigivir Soproxil 400 mg + TAF |
|---|---|---|---|---|---|
| Carpal tunnel syndromeNervous system disorders | 0/30 | 1/12 | 0/30 | 0/21 | 0/30 |
| Abdominal pain upperGastrointestinal disorders | 0/30 | 0/12 | 1/30 | 0/21 | 0/30 |
| Campylobacter gastroenteritisInfections and infestations | 1/30 | 0/12 | 0/30 | 0/21 | 0/30 |
| Alanine aminotransferase increasedInvestigations | 0/30 | 0/12 | 0/30 | 0/21 | 1/30 |
| Event | Group 1: Inarigivir Soproxil 50 mg + TAF | Group 2: TAF | Group 3: Inarigivir Soproxil 200 mg + TAF | Group 4: Inarigivir Soproxil 100 mg + Commercially Available NUC(s) | Group 5: Inarigivir Soproxil 400 mg + TAF |
|---|---|---|---|---|---|
| Influenza like illnessGeneral disorders | 0/30 | 0/12 | 2/30 | 6/21 | 1/30 |
| Upper respiratory tract infectionInfections and infestations | 1/30 | 3/12 | 6/30 | 1/21 | 3/30 |
| Alanine aminotransferase increasedInvestigations | 4/30 | 1/12 | 1/30 | 1/21 | 0/30 |
| HeadacheNervous system disorders | 1/30 | 0/12 | 3/30 | 0/21 | 2/30 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 0/30 | 0/12 | 1/30 | 0/21 | 3/30 |
| InfluenzaInfections and infestations | 1/30 | 0/12 | 0/30 | 2/21 | 0/30 |
| VertigoEar and labyrinth disorders | 0/30 | 1/12 | 0/30 | 0/21 | 0/30 |
| Hepatic steatosisHepatobiliary disorders | 0/30 | 1/12 | 0/30 | 0/21 | 0/30 |
| Tooth fractureInjury, poisoning and procedural complications | 0/30 | 1/12 | 0/30 | 0/21 | 0/30 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/30 | 1/12 | 0/30 | 0/21 | 0/30 |
The Safety Analysis Set included all participants who took at least 1 dose of any study drug.
| Age, Customized(Participants) | Group 1: Inarigivir Soproxil 50 mg + TAF | Group 2: TAF | Group 3: Inarigivir Soproxil 200 mg + TAF | Group 4: Inarigivir Soproxil 100 mg + Commercially Available NUC(s) | Group 5: Inarigivir Soproxil 400 mg + TAF | Total |
|---|---|---|---|---|---|---|
| <50 years | 23 | 5 | 19 | 11 | 13 | 71 |
| ≥50 years | 7 | 7 | 11 | 10 | 17 | 52 |
| Sex: Female, Male(Participants) | Group 1: Inarigivir Soproxil 50 mg + TAF | Group 2: TAF | Group 3: Inarigivir Soproxil 200 mg + TAF | Group 4: Inarigivir Soproxil 100 mg + Commercially Available NUC(s) | Group 5: Inarigivir Soproxil 400 mg + TAF | Total |
|---|---|---|---|---|---|---|
| Female | 12 | 3 | 11 | 9 | 11 | 46 |
| Male | 18 | 9 | 19 | 12 | 19 | 77 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: Inarigivir Soproxil 50 mg + TAF | Group 2: TAF | Group 3: Inarigivir Soproxil 200 mg + TAF | Group 4: Inarigivir Soproxil 100 mg + Commercially Available NUC(s) | Group 5: Inarigivir Soproxil 400 mg + TAF | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 30 | 12 | 30 | 21 | 30 | 123 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group 1: Inarigivir Soproxil 50 mg + TAF | Group 2: TAF | Group 3: Inarigivir Soproxil 200 mg + TAF | Group 4: Inarigivir Soproxil 100 mg + Commercially Available NUC(s) | Group 5: Inarigivir Soproxil 400 mg + TAF | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 30 | 12 | 30 | 21 | 30 | 123 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Group 1: Inarigivir Soproxil 50 mg + TAF | Group 2: TAF | Group 3: Inarigivir Soproxil 200 mg + TAF | Group 4: Inarigivir Soproxil 100 mg + Commercially Available NUC(s) | Group 5: Inarigivir Soproxil 400 mg + TAF | Total |
|---|---|---|---|---|---|---|
| Hong Kong | 8 | 5 | 22 | 11 | 30 | 76 |
| South Korea | 22 | 7 | 8 | 10 | 0 | 47 |
| Hepatitis B Surface Antigen (HBsAg) Category(Participants) | Group 1: Inarigivir Soproxil 50 mg + TAF | Group 2: TAF | Group 3: Inarigivir Soproxil 200 mg + TAF | Group 4: Inarigivir Soproxil 100 mg + Commercially Available NUC(s) | Group 5: Inarigivir Soproxil 400 mg + TAF | Total |
|---|---|---|---|---|---|---|
| ≤ 4 log10 IU/mL | 16 | 4 | 23 | 19 | 21 | 83 |
| > 4 log10 IU/mL | 14 | 8 | 7 | 2 | 9 | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2018 to primary completion in Jan 2020, 22 months.
Results were first posted in Apr 2022, 2 years 2 months after primary completion. A results delay was requested in Oct 2020.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Inarigivir soproxil · Tenofovir alafenamide